[1] Bei L, John N, Carolyn R,et al. Ovarian cancer immunotherapy: opportunities, progresses and challenges[J].J Hematol Oncol,2010, 3(1):7.
[2] Hennessy BT, Coleman RL, Markman M. Ovarian cancer[J].Lancet,2009, 374(9698):1371-1382.
[3] 苏子涵, 赵云. 靶向超声微泡在卵巢癌治疗中的研究进展[J].海南医学, 2015, 26(9):1331-1334.
[4] 孙艳. 靶向治疗对复发性耐药性卵巢癌的治疗价值分析[J].中国实用医药, 2016, 11(29):123-124.
[5] Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer[J].N Engl J Med,2012, 67(26):2473-2483.
[6] 林岩松, 王宸, 李慧,等. 甲磺酸阿帕替尼治疗进展性碘难治性甲状腺癌的短期疗效及安全性初步报告[J].中国癌症杂志, 2016, 26(9):721-726.
[7] 沈铿. 复发性卵巢癌的诊断和治疗策略[J].现代妇产科进展, 2005, 14(3):177-180.
[8] Cohn DE, Valmadre S, Resnick KE, et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer[J].Gynecol Oncol,2006, 102(2):134-139. |
2019, Vol. 36 
